SOUTH
SAN FRANCISCO, Calif., Oct. 4, 2024
/PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics, announced a late-breaking
oral presentation of the Phase 1 expansion results of IDE397, a
first-in-class, oral, MAT2A inhibitor in methylthioadenosine
phosphorylase (MTAP)-deletion urothelial and non-small cell lung
cancer (NSCLC) patients at the 36th edition of the EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics taking place
on October 23 to 25, 2024, in
Barcelona, Spain. In
addition, IDEAYA will also have additional poster presentations at
the EORTC-NCI-AACR Symposium highlighting preclinical data for the
MAT2A and PARG programs.
Details for the oral presentation are as follows:
Presenter: Dr. Benjamin Herzberg, MD, Assistant
Professor, Columbia University
Title: Phase 1 expansion results of IDE397, a
first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del)
non-small cell lung cancer (NSCLC) and urothelial cancer (UC)
Abstract #: 501 LBA
Session: Plenary Session 7, Late Breaking Abstracts and
Proffered Papers: Novel discoveries in drug development
Date and Time: Friday, October 25, 2024 at 3:00pm CEST
Poster presentation details are below:
Author: Garbett, D. et al.
Title: The mechanistic basis of both deep and durable
antitumor activity by combinatorial inhibition of MAT2A and PRMT5
in MTAP-deleted tumors
Poster Number: PB204
Session Title: Combination Therapies
Date and Time: Thursday, October 24,
2024, 9:00am - 5:30pm CEST,
Exhibition Hall
Author: Munoz, D. et al.
Title: IDE161, a potential first-in-class clinical
candidate PARG inhibitor, selectively targets solid tumors with
replication stress and DNA repair vulnerabilities
Poster Number: PB337
Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR,
ATM)
Date and Time: Friday, October 25, 2024, 9:00am - 3:00pm CEST, Exhibition Hall
The oral presentation and posters will be available online at
https://ir.ideayabio.com/events following the presentations.
About IDEAYA Biosciences
IDEAYA is a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
research and drug discovery capabilities to synthetic lethality –
which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to the timing and content of future
presentations. Such forward-looking statements involve substantial
risks and uncertainties that could cause IDEAYA's preclinical
and clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the drug development process, including IDEAYA's programs' early
stage of development, the process of designing and conducting
preclinical and clinical trials, the regulatory approval processes,
the timing of regulatory filings, the challenges associated with
manufacturing drug products, IDEAYA's ability to successfully
establish, protect and defend its intellectual property, and other
matters that could affect the sufficiency of existing cash to fund
operations. IDEAYA undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of IDEAYA in general, see IDEAYA's
Annual Report on Form 10-K dated February
20, 2024 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-late-breaker-oral-presentation-of-ide397-phase-1-expansion-results-in-mtap-deletion-lung-and-urothelial-cancer-at-the-36th-edition-of-the-eortc-nci-aacr-symposium-302267595.html
SOURCE IDEAYA Biosciences, Inc.
